Drug Type Monoclonal antibody |
Synonyms YBL 006, YBL-006 |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhasePendingPhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 2 | United States | 01 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Australia | 01 Jul 2020 | |
Advanced Malignant Solid Neoplasm | Phase 2 | Thailand | 01 Jul 2020 |
Phase 1/2 | Advanced Malignant Solid Neoplasm TIL | TMB-H | MSI-H | - | tbzeaudxfz(zmwkbxwxnk) = jyulmyykqz eqsxcqyhqm (gtbxnlxsku ) View more | Positive | 02 Nov 2023 | ||
NCT04450901 (ASCO2022) Manual | Phase 1 | 67 | bkkgepnvxb(ctkvjcwaok) = fatigue (19.4%), pruritus (10.4%), and fever (7.5%), and two hypothyroidism (3.0%), one pneumonitis (1.5%), and one cytokine-releasing syndrome (1.5%) were observed. qfsuykcnfk (dqjczynois ) View more | Positive | 02 Jun 2022 | ||
YBL-006 200 mg Q2W | |||||||
Phase 1 | 10 | indjramswe(jbvrzocesu) = iifpriwvlc xbhbvhqxhf (pximzuxwch ) | Positive | 16 Sep 2021 | |||
Phase 1 | 8 | kjqavetuou(clfitvoznf) = qqzmyvkmql zhptlebyho (jeresmygtz ) | - | 28 May 2021 |